Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Cancer Stem Cell Effects of Proenzymes
13 August 2019 - - Australian biopharmaceutical company Propanc Biopharma, Inc.'s (OTC: PPCB) scientific researchers, together with its joint research partners, Universities of Jaén and Granada, have published key data in a peer reviewed journal, Scientific Reports, confirming the mechanism of proenzymes and its anti-cancer effects against cancer stem cells, the company said.

From the publishers of Nature, it is an online, open access journal, which publishes primary research from all areas of the natural and clinical sciences.

According to the company, the data provides the strongest evidence that proenzymes could be an effective tool in the fight against metastatic cancer, the single biggest cause of patient death for sufferers.

The company's lead product candidate, PRP, is a formulation of two proenzymes, designed to act synergistically against solid tumors which are malignant.

PRP is currently in preparation for a First-In-Human study in advanced cancer patients which the company plans to commence in 2020.

To explain the significance of the discovery, people often have the misconception that tumors are made up from the same type of malignant cell that grows uncontrollably and exponentially.

Although that could be the first impression when a tumors progress rapidly, in fact, tumors are a very complicated kind of new organ that develops an intricate organisation with its own blood supply and an intricate communication system with the rest of the organism that facilitates the cancer dispersion.

In addition, there are different types of cells within a tumor mass, it is true that all of them have a common feature, they are undifferentiated cells, but some of them are more "ancestral" than others. These cells are named cancer stem cells, or CSCs, and are responsible for tumor metastasis and tumor relapse.

The strength of these particular cells is that they do not replicate, so conventional therapies that only affect growing cells, do not harm CSCs.

Other important facts about tumors is their ability to change their surroundings, inducing neighbouring cells to become malignant, and even more worrisome, its ability to corrupt distant tissue cells creating a future tumor microenvironment.

After more than 10 years collaboration with Propanc's prestigious, joint scientific researchers with significant experience in cancer, the company now understands the mechanism of action of PRP, a formulation containing a synergistic combination of two pancreatic proenzymes.

The "beauty" of this naturally derived formulation is that the body has designed enzymes to perform a specific role on the cells to orchestrate gradual changes.

In the same pathways that active enzymes work on healthy cells, PRP, once converted to the activated enzyme form, changes the malignant nature of cancer cells toward a differentiated state in which cells return to be what they were.

Some of the company's scientific studies have already been published in high impact journals, demonstrating that PRP decreases cell proliferation and migration, induces cell differentiation and impairs angiogenesis. In short, tumors cannot grow after PRP treatment, as demonstrated by in vivo studies with mice models.

This latest achievement has demonstrated that PRP also has a significant effect on that population of cells within the tumor that keep a dormant state and a stemness nature.

As said above, those cells, called CSCs, are not eradicated by conventional therapies and are responsible for generating a new tumor in other organs, a process known as metastasis, which is the main cause of patient death for sufferers.

The company has also been working with its research partners with the aim of enhancing the effects of PRP, whilst also maximizing a better-quality and safer product. The project is progressing well and on track to produce an optimized version of PRP which could be effectively reproduced with enhanced effects, compared to the naturally derived proenzymes.

Further work is currently being undertaken to ensure the product is comparable in structure to PRP.

Propanc Biopharma is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers.